文献速递脑血管病

POINT试验:轻型卒中与短暂性脑缺血发作后的残疾结局

Disability After Minor Stroke and Transient Ischemic Attack in the POINT Trial.
PubMed 文献 · Stroke · 2020-02-12

POINT试验事后探索性分析比较阿司匹林联合氯吡格雷双联抗血小板治疗与单用阿司匹林对90天残疾的影响。总体残疾率两组相似,但双联治疗组归因于索引事件或复发性卒中的残疾显著更少,提示双联治疗可能减少卒中相关残疾。

要点

  • 双联抗血小板未降低总体残疾率(14.7% vs 14.3%)。
  • 双联治疗组归因于索引事件或复发卒中的残疾显著更少(5.9% vs 7.4%)。
  • 残疾差异主要来自索引事件相关残疾(4.5% vs 6.0%)。

核心结论

  • 在急性轻型卒中和TIA患者中,双联抗血小板治疗除减少复发性卒中外,可能减少卒中相关残疾。

研究设计与样本

  • POINT试验事后探索性分析,纳入TIA或轻型卒中(NIHSS≤3)且发病12小时内的患者,随机接受阿司匹林加氯吡格雷双联治疗或单用阿司匹林。

主要发现

  • 90天时,TIA患者中188/1964(9.6%)残疾,卒中患者中471/2586(18.2%)残疾。
  • 总体残疾率双联组与单用阿司匹林组相似(14.7% vs 14.3%;OR 0.97,95%CI 0.82-1.14;P=0.69)。
  • 双联组发生主要结局事件且残疾的患者数数值上更少(3.0% vs 4.0%;OR 0.73,95%CI 0.53-1.01;P=0.06)。
  • 双联组研究者归因于索引事件或复发性卒中的残疾显著更少(5.9% vs 7.4%;OR 0.78,95%CI 0.62-0.99;P=0.04)。
  • 归因于索引事件的残疾差异显著(4.5% vs 6.0%;OR 0.74,95%CI 0.57-0.96;P=0.02)。

关键数值与推荐

  • TIA患者残疾的多变量预测因素包括年龄、后续缺血性卒中、严重不良事件和大出血。
  • 卒中患者残疾的多变量预测因素包括女性、高血压或糖尿病、NIHSS评分、复发性缺血性卒中、后续心肌梗死和严重不良事件。

临床怎么用

  • 对于急性轻型卒中或TIA患者,双联抗血小板治疗可能不仅减少复发性卒中,还可能减少卒中相关残疾。

局限性

  • 本分析为事后探索性分析,结果需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- While combination aspirin and clopidogrel reduces recurrent stroke compared with aspirin alone in patients with transient ischemic attack (TIA) or minor stroke, the effect on disability is uncertain. Methods- The POINT trial (Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke) randomized patients with TIA or minor stroke (National Institutes of Health Stroke Scale score ≤3) within 12 hours of onset to dual antiplatelet therapy (DAPT) with aspirin plus clopidogrel versus aspirin alone. The primary outcome measure was a composite of stroke, myocardial infarction, or vascular death. We performed a post hoc exploratory analysis to examine the effect of treatment on overall disability (defined as modified Rankin Scale score >1) at 90 days, as well as disability ascribed by the local investigator to index or recurrent stroke. We also evaluated predictors of disability. Results- At 90 days, 188 of 1964 (9.6%) of patients enrolled with TIA and 471 of 2586 (18.2%) of those enrolled with stroke were disabled. Overall disability was similar between patients assigned DAPT versus aspirin alone (14.7% versus 14.3%; odds ratio, 0.97 [95% CI, 0.82-1.14]; P=0.69). However, there were numerically fewer patients with disability in conjunction with a primary outcome event in the DAPT arm (3.0% versus 4.0%; odds ratio, 0.73 [95% CI, 0.53-1.01]; P=0.06) and significantly fewer patients in the DAPT arm with disability attributed by the investigators to either the index event or recurrent stroke (5.9% versus 7.4%; odds ratio, 0.78 [95% CI, 0.62-0.99]; P=0.04). Notably, disability attributed to the index event accounted for the majority of this difference (4.5% versus 6.0%; odds ratio, 0.74 [95% CI, 0.57-0.96]; P=0.02). In multivariate analysis, age, subsequent ischemic stroke, serious adverse events, and major bleeding were significantly associated with disability in TIA; for those with stroke, female sex, hypertension, or diabetes mellitus, National Institutes of Health Stroke Scale score, recurrent ischemic stroke, subsequent myocardial infarction, and serious adverse events were associated with disability. Conclusions- In addition to reducing recurrent stroke in patients with acute minor stroke and TIA, DAPT might reduce stroke-related disability. Registration- URL: https://www.clinicaltrials.gov. Unique identifier: NCT00991029.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Cucchiara B, Elm J, Easton JD, et al. Disability After Minor Stroke and Transient Ischemic Attack in the POINT Trial. Stroke. 2020. PMID: 32078486. doi:10.1161/STROKEAHA.119.027465

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。